KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Sarepta Therapeutics (SRPT) over the last 10 years, with Q2 2025 value amounting to $153.2 million.

  • Sarepta Therapeutics' Other Operating Expenses changed N/A to $153.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $153.2 million, marking a year-over-year increase of 19950.16%. This contributed to the annual value of $102.0 million for FY2023, which is N/A changed from last year.
  • As of Q2 2025, Sarepta Therapeutics' Other Operating Expenses stood at $153.2 million.
  • Sarepta Therapeutics' 5-year Other Operating Expenses high stood at $153.2 million for Q2 2025, and its period low was $31.6 million during Q1 2022.
  • Its 5-year average for Other Operating Expenses is $72.5 million, with a median of $51.2 million in 2024.
  • The largest annual percentage gain for Sarepta Therapeutics' Other Operating Expenses in the last 5 years was 91947.46% (2021), contrasted with its biggest fall of 6991.18% (2021).
  • Sarepta Therapeutics' Other Operating Expenses (Quarter) stood at $102.0 million in 2021, then crashed by 69.0% to $31.6 million in 2022, then soared by 222.57% to $102.0 million in 2023, then tumbled by 49.84% to $51.2 million in 2024, then surged by 199.5% to $153.2 million in 2025.
  • Its Other Operating Expenses stands at $153.2 million for Q2 2025, versus $51.2 million for Q1 2024 and $102.0 million for Q2 2023.